Early osteoarthritis in heritable disorders of connective tissue: TGF-β-associated endophenotypes and subchondral bone remodeling

1. Alekseeva LI, Taskina EA, Kashevarova NG. [Osteoarthritis: Epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(2):9–21 (In Russ.)].

EDN: GIKYDR. https://doi.org/10.14412/1996-7012-2019-2-9-21

2. Akatova EV, Arutyunov GP, Baranov AA, Butolin EG, Vereshchagina GN, Vershinina MV, et al. [Clinical guidelines. Undifferentiated connective tissue disease. Terapiya = Therapy. 2024;10(S5):1–43 (In Russ)].

EDN: XBFRFF. https://doi.org/10.18565/therapy.2024.5suppl.1-43

3. Kadurina TI, Gorbunova VN, Abbakumova LN, Brzhesky VV, Vershinina MV, Vorontsova TN, et al. [Connective tissue dysplasia. A guide for physicians. Saint Petersburg: Elbi-SPb. 2009; 704 pp. (In Russ.)].

EDN: QLTVMP. ISBN: 978-5-93979-215-8.

4. Ramirez F., Caescu C., Wondimu E., Galatioto J. Marfan syndrome; A connective tissue disease at the crossroads of mechanotransduction, TGFβ signaling and cell stemness. Matrix Biol. 2018;71–72:82–89.

PMID: 28782645. PMCID: PMC5797509. https://doi.org/10.1016/j.matbio.2017.07.004

5. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476–85.

PMID: 20591885. https://doi.org/10.1136/jmg.2009.072785

6. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, et al. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33(3):407–11.

PMID: 12598898. https://doi.org/10.1038/ng1116

7. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312(5770):117–21.

PMID: 16601194. PMCID: PMC1482474. https://doi.org/10.1126/science.1124287

8. Morita M, Arshad F, Quayle LA, George CN, Lefley DV, Kalajzic I, et al. Losartan alters osteoblast differentiation and increases bone mass through inhibition of TGF-β signalling in vitro and in an OIM mouse model. Bone Rep. 2024;22:101795.

PMID: 39185375. PMCID: PMC11344016. https://doi.org/10.1016/j.bonr.2024.101795

9. Judge DP, Dietz HC. Marfan’s syndrome. Lancet. 2005;366(9501):1965–76.

PMID: 16325700. PMCID: PMC1513064. https://doi.org/10.1016/S0140-6736(05)67789-6

10. Smaldone S, Ramirez F. Fibrillin microfibrils in bone physiology. Matrix Biol. 2016;52–54:191–97.

PMID: 26408953. PMCID: PMC4808491. https://doi.org/10.1016/j.matbio.2015.09.004

11. Trifiro G, Marelli S, Viecca M, Mora S, Pini A. Areal bone mineral density in children and adolescents with Marfan syndrome: Evidence of an evolving problem. Bone. 2015;73:176–80.

PMID: 25511867. https://doi.org/10.1016/j.bone.2014.12.006

12. Rifkin DB, Todorovic V. Bone matrix to growth factors: Location, location, location. J Cell Biol. 2010;190(6):949–51.

PMID: 20855500. PMCID: PMC3101590. https://doi.org/10.1083/jcb.201008116

13. Ramirez F, Rifkin DB. Extracellular microfibrils: Contextual platforms for TGFbeta and BMP signaling. Curr Opin Cell Biol. 2009;21(5):616–22.

PMID: 19525102. PMCID: PMC2767232. https://doi.org/10.1016/j.ceb.2009.05.00

14. Arteaga-Solis E, Gayraud B, Lee SY, Shum L, Sakai L, Ramirez F. Regulation of limb patterning by extracellular microfibrils. J Cell Biol. 2001;154(2):275–81.

PMID: 11470817. PMCID: PMC2150751. https://doi.org/10.1083/jcb.200105046

15. Sengle G, Charbonneau NL, Ono RN, Sasaki T, Alvarez J, Keene DR, et al. Targeting of bone morphogenetic protein growth factor complexes to fibrillin. J Biol Chem. 2008;283(20):13874–88.

PMID: 18339631. PMCID: PMC2376219. https://doi.org/10.1074/jbc.M707820200

16. Arsentev VG, Kadurina TI, Abbakumova LN. [New principles of diagnosis and classification of the Ehlers–Danlos syndrome. Pediatr = The Pediatrician. 2018;9(1):118–125 (In Russ.)].

EDN: YWORWU. https://doi.org/10.17816/PED91118-125

17. Satybaldyev AM. [Joint hypermobility syndrome in rheumatology. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017;11(2):68–74 (In Russ.)].

EDN: YTFIBR. https://doi.org/10.14412/1996-7012-2017-2-68-74

18. Beighton P, Solomon L, Soskolne CL. Articular mobility in an African population. Ann Rheum Dis. 1973;32(5):413–18.

PMID: 4751776. PMCID: PMC1006136. https://doi.org/10.1136/ard.32.5.413

19. Grahame R, Bird HA, Child A. The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS). J Rheumatol. 2000;27(7):1777–79. PMID: 10914867.

20. Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A. A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet. 2017;175(1):148–57.

PMID: 28145606. https://doi.org/10.1002/ajmg.c.31539

21. Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8–26.

PMID: 28306229. https://doi.org/10.1002/ajmg.c.31552

22. Castori M, Camerota F, Celletti C, Danese C, Santilli V, Saraceni VM, Grammatico P. Natural history and manifestations of the hypermobility type Ehlers–Danlos syndrome: A pilot study on 21 patients. Am J Med Genet A. 2010;152A(3):556–64.

PMID: 20140961. https://doi.org/10.1002/ajmg.a.33231

23. Rombaut L, Malfait F, Cools A, De Paepe A, Calders P. Musculoskeletal complaints, physical activity and health-related quality of life among patients with the Ehlers–Danlos syndrome hypermobility type. Disabil Rehabil. 2010;32(16):1339–45.

PMID: 20156051. https://doi.org/10.3109/09638280903514739

24. Coussens M, Banica T, Lapauw B, De Wandele I, Rombaut L, Malfait F, Calders P. Bone parameters in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder: A comparative cross-sectional study. Bone. 2023;166:116583.

PMID: 36243401. https://doi.org/10.1016/j.bone.2022.116583

25. Roemer FW, Jarraya M, Collins JE, Kwoh CK, Hayashi D, Hunter DJ, Guermazi A. Structural phenotypes of knee osteoarthritis: Potential clinical and research relevance. Skeletal Radiol. 2023;52(11):2021–30.

PMID: 36161341. PMCID: PMC10509066. https://doi.org/10.1007/s00256-022-04191-6

26. van de Laar IM, van der Linde D, Oei EH, Bos PK, Bessems JH, Bierma-Zeinstra SM, et al. Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med Genet. 2012;49(1):47–57.

PMID: 22167769. https://doi.org/10.1136/jmedgenet-2011-10038

27. Regalado ES, Guo DC, Villamizar C, Avidan N, Gilchrist D, McGillivray B, et al.; NHLBI GO Exome Sequencing Project. Exome sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms. Circ Res. 2011;109(6):680–86.

PMID: 21778426. PMCID: PMC4115811. https://doi.org/10.1161/CIRCRESAHA.111.248161

28. Massague J. TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616–30.

PMID: 22992590. PMCID: PMC4027049. https://doi.org/10.1038/nrm3434

29. Lindsay ME, Dietz HC. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature. 2011;473(7347):308–16.

PMID: 21593863. PMCID: PMC3622871. https://doi.org/10.1038/nature10145

30. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, et al. Aneurysm syndromes caused by mutations in the TGF-β receptor. N Engl J Med. 2006;355(8):788–98.

PMID: 16928994. https://doi.org/10.1056/NEJMoa055695

31. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. 2005;37(3):275–81.

PMID: 15731757. https://doi.org/10.1038/ng1511

32. MacCarrick G, Black JH 3rd, Bowdin S, El-Hamamsy I, Frischmeyer-Guerrerio PA, Guerrerio AL, et al. Loeys–Dietz syndrome: A primer for diagnosis and management. Genet Med. 2014;16(8):576–87.

PMID: 24577266. PMCID: PMC4131122. https://doi.org/10.1038/gim.2014.11

33. Chaugule S, Constantinou CK, John AA, Micha D, Eekhoff M, Gravallese E, et al. Comprehensive review of osteogenesis imperfecta: Current treatments and future innovations. Hum Gene Ther. 2025;36(5–6):597–617.

PMID: 39932815. PMCID: PMC11971546. https://doi.org/10.1089/hum.2024.191

34. Jovanovic M, Marini JC. Update on the genetics of osteogenesis imperfecta. Calcif Tissue Int. 2024;115(6):891–914.

PMID: 39127989. PMCID: PMC11607015. https://doi.org/10.1007/s00223-024-01266-5

35. Celli L, Garrelfs MR, Sakkers RJB, Elting MW, Celli M, Bokenkamp A, et al. Adapting to adulthood: A review of transition strategies for osteogenesis imperfecta. Calcif Tissue Int. 2024;115(6):960–75.

PMID: 39535563. PMCID: PMC11607004. https://doi.org/10.1007/s00223-024-01305-1

36. Lajeunesse D, Reboul P. Subchondral bone in osteoarthritis: A biologic link with articular cartilage leading to abnormal remodeling. Curr Opin Rheumatol. 2003;15(5):628–33.

PMID: 12960492. https://doi.org/10.1097/00002281-200309000-00018

37. Lila AM, Alekseeva LI, Telyshev KA. [Current approaches to osteoarthritis phenotyping. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(2):4–8 (In Russ.)].

EDN: ZSJJFZ. https://doi.org/10.14412/1996-7012-2019-2-4-8

38. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745–59.

PMID: 31034380. https://doi.org/10.1016/S0140-6736(19)30417-9

39. Dole NS, Mazur CM, Acevedo C, Lopez JP, Monteiro DA, Fowler TW, et al. Osteocyte-intrinsic TGF-β signaling regulates bone quality through perilacunar/canalicular remodeling. Cell Rep. 2017;21(9):2585–96.

PMID: 29186693. PMCID: PMC6014615. https://doi.org/10.1016/j.celrep.2017.10.115

40. Peng R, Lin Q, Yang Z, Li H, Li JJ, Xing D. Fibroblast – myofibroblast transition in osteoarthritis: Current insights. Int J Mol Sci. 2025;26(16):7881.

PMID: 40869202. PMCID: PMC12386718. https://doi.org/10.3390/ijms26167881

41. Carthy JM. TGFβ signaling and the control of myofibroblast differentiation: Implications for chronic inflammatory disorders. J Cell Physiol. 2018;233(1):98–106.

PMID: 28247933. https://doi.org/10.1002/jcp.25879

42. Rudoy AS, Letkovskaya TA, Uryvaev AM, Reutsky IP. [Role of TGF‑β induction and gastrointestinal myofibroblasts in the pathomorphogenesis of chronic gastritis in patients with Marfan syndrome and Marfan‑like states. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2016;(6):14–18 (In Russ.)]. EDN: WKGOQV.

43. Rudoy AS, Uryvaev AM. [Pathogenesis of pre-malignant gastric lesions in patients with Marfan syndrome. Terapiya = Therapy. 2020;6(6):71–81 (In Russ.)].

EDN: LOHUGP. https://doi.org/10.18565/therapy.2020.6.71-81

44. Valiuzhenich YaI, Udina OA, Rudoy AS. [Role of transforming growth factor β in morphogenesis of dilation and dissection of the thoracic aorta. Kardiologiya v Belarusi = Cardiology in Belarus. 2022;14(5):564–77 (In Russ.)].

EDN: UYDULR. https://doi.org/10.34883/PI.2022.14.5.003

45. Tachmazidou I, Hatzikotoulas K, Southam L, Esparza-Gordillo J, Haberland V, Zheng J, et al. Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. Nat Gen. 2019;51(2):230–36.

PMID: 30664745. PMCID: PMC6400267. https://doi.org/10.1038/s41588-018-0321-5

46. Zhai G, Dore J, Rahman P. TGF-β signal transduction pathways and osteoarthritis. Rheumatol Int.. 2015;35(8):1283–92.

PMID: 25773660. https://doi.org/10.1007/s00296-015-3251-z

47. Sun Y, Li L, Wang J, Liu H, Wang H. Emerging landscape of osteogenesis imperfecta pathogenesis and therapeutic approaches. ACS Pharmacol Transl Sci. 2024;7(1):72–96.

PMID: 38230285. PMCID: PMC10789133. https://doi.org/10.1021/acsptsci.3c00324

48. Hasegawa K. Osteogenesis imperfecta: Pathogenesis, classification, and treatment. Clin Pediatr Endocrinol. 2025;34(3):152–61.

PMID: 40636817. PMCID: PMC12236168. https://doi.org/10.1297/cpe.2025-0009